Many people with IBD, an umbrella term that includes ulcerative colitis and Crohn's disease, have a reduced quality of life, ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by ...

Dr Ray O’Connor takes a look at the latest clinical articles on inflammatory bowel disease ...

Researchers at University of Miami Miller School of Medicine were awarded a $2.9 million grant by the NIH to study the genetic data of more than 3,000 Hispanic individuals to better understand ...

Previous studies have measured the prevalence of LTBI and TB disease among child household contacts of patients with DR-TB,5–11 but have rarely conducted a contact investigation prospectively.5 7 We ...

Introduction Inflammatory bowel diseases (IBDs) are chronic diseases of unknown cause characterised by a progressive and unpredictable disease course. In the last decade, biological treatment has ...

Two years ago, 10-year-old Bo Bratschie experienced weight loss and high fevers, leading to many hospital visits before being ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for ...

Subgroup analyses in patients with Crohn's disease revealed a pooled prevalence of depression symptoms in patients with active disease of 51·0% (95% CI 31·0–70·8) in five studies, 19,53,70,84,101 and ...

AbstractPurpose:. Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims ...

We thank Dr Yang and colleagues for their interest in the HELIOS trial and their thoughtful appraisal of our findings.1 2 Yang et al highlight the possibility that heterogeneity in endoscopist ...